Abstract:Summary Background There is debate about the generalisability of results from randomised clinical trials (RCTs) to real-world settings. Studying outcomes of treatments for schizophrenia can shed light on this issue and inform treatment guidelines. We therefore compared the efficacy and effectiveness of antipsychotics for relapse prevention in schizophrenia and estimated overall treatment effects using all available RCT and real-world evidence. Methods We conducted network meta-analyses using individual participant data from Swedish and Finnish national registries and aggregate data from RCTs. The target population was adults (age >18 and <65 years) with schizophrenia and schizoaffective disorder with stabilised symptoms. We analysed each registry separately to obtain hazard ratios (HRs) and 95% CIs for relapse within 6 months post-antipsychotic initiation as our main outcome. Interventions studied were antipsychotics, no antipsychotic use, and placebo. We compared HRs versus a reference drug (oral haloperidol) between registries, and between registry individuals who would be eligible and ineligible for RCTs, using the ratio of HRs. We synthesised evidence using network meta-analysis and compared results from our network meta-analysis of real-world data with our network meta-analysis of RCT data, including oral versus long-acting injectable (LAI) formulations. Finally, we conducted a joint real-world and RCT network meta-analysis. Findings We included 90 469 individuals from the Swedish and Finnish registries (mean age 45·9 [SD 14·6] years; 43 025 [47·5%] women and 47 467 [52·5%] men, ethnicity data unavailable) and 10 091 individuals from 30 RCTs (mean age 39·6 years [SD 11·7]; 3724 [36·9%] women and 6367 [63·1%] men, 6022 White [59·7%]). We found good agreement in effectiveness of antipsychotics between Swedish and Finnish registries (HR ratio 0·97, 95% CI 0·88–1·08). Drug effectiveness versus no antipsychotic was larger in RCT-eligible than RCT-ineligible individuals (HR ratio 1·40 [1·24–1·59]). Efficacy versus placebo in RCTs was larger than effectiveness versus no antipsychotic in real-world (HR ratio 2·58 [2·02–3·30]). We found no evidence of differences between effectiveness and efficacy for between-drug comparisons (HR ratio vs oral haloperidol 1·17 [0·83–1·65], where HR ratio >1 means superior effectiveness in real-world to RCTs), except for LAI versus oral comparisons (HR ratio 0·73 [0·53–0·99], indicating superior effectiveness in real-world data relative to RCTs). The real-world network meta-analysis showed clozapine was most effective, followed by olanzapine LAI. The RCT network meta-analysis exhibited heterogeneity and inconsistency. The joint real-world and RCT network meta-analysis identified olanzapine as the most efficacious antipsychotic amongst those present in both RCTs and the real world registries. Interpretation LAI antipsychotics perform slightly better in the real world than according to RCTs. Otherwise, RCT evidence was in line with real-world evidence for most between-drug comparisons, but RCTs might overestimate effectiveness of antipsychotics observed in routine care settings. Our results further the understanding of the generalisability of RCT findings to clinical practice and can inform preferential prescribing guidelines. Funding None.

Therapeutic Outcomes Wide Association Scan of Different Antipsychotics in Patients with Schizophrenia: Randomized Clinical Trials and Multi-Ancestry Validation

Protocol for a Pharmacogenomic Study on Individualised Antipsychotic Drug Treatment for Patients with Schizophrenia.

Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia A Randomized, Double-Blind, Multicenter Study

Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia

Metabolic Effects Of 7 Antipsychotics On Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial

Refining antipsychotic treatment strategies in schizophrenia: discovery of genetic biomarkers for enhanced drug response prediction

Longitudinal Trajectory Analysis of Antipsychotic Response in Patients with Schizophrenia: 6-Week, Randomised, Open-Label, Multicentre Clinical Trial

Association of Telomere Length and Mitochondrial DNA Copy Number with Risperidone Treatment Response in First-Episode Antipsychotic-Naïve Schizophrenia

Comparative Effectiveness of Antipsychotics in Patients With Schizophrenia Spectrum Disorder

Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data

Safety and related factors of treatment with long-term atypical antipsychotic in Chinese patients with schizophrenia: observational study

Real-World Effectiveness, Economic, and Humanistic Outcomes of Selected Oral Antipsychotics in Patients with Schizophrenia: A Systematic Review Evaluating Global Evidence

Effects of Antipsychotic Medications on Quality of Life and Psychosocial Functioning in Patients with Early-Stage Schizophrenia: 1-Year Follow-Up Naturalistic Study

Effects Of Olanzapine, Quetiapine, And Risperidone On Neurocognitive Function In Early Psychosis: A Randomized, Double-Blind 52-Week Comparison

Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics

Long-Term Antipsychotic Effectiveness and Comparison of the Efficacy of Monotherapy and Polypharmacy in Schizophrenia: A 3-Years Follow-Up "real World" Study in China.

Five Novel Loci Associated with Antipsychotic Treatment Response in Patients with Schizophrenia: a Genome-Wide Association Study

Long‐term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta‐analysis

Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial - CORRIGENDUM.

Evaluation of Clinical Correlation between Insulin Resistance and Antipsychotic Drug Therapy in Patients with Schizophrenia

Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis